Pargyline

Overview

Pargyline, sold under the brand name Eutonyl among others, is a monoamine oxidase inhibitor (MAOI) medication which has been used to treat hypertension (high blood pressure) but is no longer marketed. It has also been studied as an antidepressant, but was never licensed for use in the treatment of depression. The drug is taken by mouth.[1–7] WP

Side effects of pargyline include orthostatic hypotension among others. It has the potential for serious food and drug interactions with sympathomimetic agents like tyramine that can result in hypertensive crisis. Pargyline acts as a non-selective and irreversible inhibitor of the monoamine oxidases MAO-A and MAO-B. The exact mechanism of the hypotensive effects of pargyline and other MAOIs is unclear. Structurally, pargyline is a benzylamine derivative and is related to selegiline and clorgyline.[3][6][8–14] WP

Pargyline was first described in 1960 and was introduced for medical use in 1963. It was available in the United States and the United Kingdom. The clinical use of pargyline was limited due to its side effects and interactions. The drug remained available in the United States as late as 2000, but was fully discontinued worldwide by 2007.[2][6][7][8][15–18] WP

Drug class

Antihypertensive monoamine oxidase inhibitor WP

From the Wikipedia article's infobox.

Uses, dosage and effects

Medical uses

Pargyline is used as an antihypertensive agent in the treatment of hypertension (high blood pressure). The dosage was 12.5 to 200 mg per day. Its onset of action is slow and several weeks of continuous administration are required for the effects to develop fully upon initiation of treatment. The decrease in blood pressure with pargyline is described as impressive and is especially strong when standing. However, the blood pressure decrease with pargyline is often difficult to control adequately.[6][11] WP

Pargyline shares its mechanism of action, monoamine oxidase inhibition, with a class of antidepressants that includes phenelzine, tranylcypromine, and isocarboxazid, among others. However, unlike other MAOIs, pargyline itself was never licensed for treatment of depression. In any case, the drug was studied in the treatment of depression and was advertised in the 1960s as an antihypertensive agent that also "brightens emotional outlook".[2–5][17] WP

Risks and side effects

Side effects

Orthostatic hypotension (excessively low blood pressure when standing or standing up) is a prominent side effect of pargyline. Other side effects include dry mouth, dizziness, nausea, headaches, increased appetite, nervousness, insomnia, agitation, sedation, manic reactions, and psychotic reactions.[5][6][11] WP

Interactions

Interactions

Pargyline has the potential for serious food and drug interactions due to its MAOI actions. This includes hypertensive crisis with intake of norepinephrine releasing agents like tyramine, amphetamine, and ephedrine. Tyramine is found in high concentrations in certain cheeses and other foods and can result in hypertensive crisis often referred to as the "cheese reaction". Episodes of hypertensive crisis can be severe or fatal and this has greatly limited the clinical use of pargyline. Hypertensive crisis with pargyline is treated intravenously with sympatholytic alpha blockers like phentolamine.[3][6] WP

Combination of pargyline and the antihypertensive agent methyldopa has been found to result in intense and potentially fatal central nervous system excitation in rodents. This has been said to resemble the effects of amphetamine overdose. The interaction appears to be due to inhibition by pargyline of the metabolism of normally short-lived methyldopa metabolites like α-methyldopamine and α-methylnorepinephrine that act as potent catecholamine releasing agents. Visual hallucinations have been reported with coadministration of pargyline and methyldopa in humans. As such, use of methyldopa in combination with pargyline and other MAOIs is contraindicated.[11][19–23] WP

Pargyline is also a disulfiram-like drug and aldehyde dehydrogenase (ALDH) inhibitor similarly to disulfiram and can produce alcohol intolerance-type reactions with alcohol.[11][24][25] WP

Pharmacology

Monoamine oxidase inhibition

Pargyline is a non-selective and irreversible monoamine oxidase inhibitor (MAOI), or an inhibitor of the monoamine oxidase (MAO) enzyme. This enzyme is involved in the metabolism of the monoamine neurotransmitters serotonin, norepinephrine, and dopamine. Pargyline is said to have slight preference or selectivity for inhibition of MAO-B over MAO-A (IC₅₀ (half-maximal inhibitory concentration) = 8.20 nM and 11.52 nM, respectively). Using rodent systems however, pargyline showed 2- to 356-fold selectivity for MAO-B inhibition over MAO-A inhibition in different studies (compared to 16- to 6401-fold selectivity with selegiline). In relation to the preceding, pargyline has been referred to as a so-called semi-selective MAO-B inhibitor. It has also been found to show some selectivity for MAO-B inhibition with a single dose but results in non-selective inhibition with continuous administration.[3][26–32] WP

Pargyline produces its antihypertensive effects via MAO inhibition. However, the exact mechanism of action by which this occurs is unclear. Pargyline and other MAOIs inhibit the metabolism of norepinephrine and cause accumulation of norepinephrine in the heart, brain, and other adrenergic tissues. Some possibilities include diminished responsiveness to norepinephrine via increased norepinephrine levels in blood vessels and blockade of the release of norepinephrine from peripheral sympathetic neurons. Another possibility is that pargyline increases levels of false neurotransmitters like octopamine and tyramine, which are weaker pressor agents than norepinephrine. However, the involvement of octopamine in the hypotensive effects of pargyline and other MAOIs is uncertain. Yet another possibility is that the hypotensive effects may be due to accumulation of N-acetylserotonin, which shows antihypertensive effects in animals. As of 2018, the precise mechanism of the hypotensive effects of MAOIs still remains unresolved.[6][8–11][33][34] WP

Other actions

In addition to its actions as an MAOI, pargyline has been found to bind with high affinity to the I₂ imidazoline receptor. This receptor has been found to actually be an allosteric site on the monoamine oxidase (MAO) enzyme.[3][35] WP

A high dose of pargyline (10 mg/kg) has been found to stimulate locomotor activity, a psychostimulant-like effect, in certain behavioral tests in rats. This might be due to its MAOI activity and increased dopamine levels in the nucleus accumbens or might be related to stimulant-like effects of its metabolites including benzylamine, N-methylbenzylamine, and/or N-propargylbenzylamine. However, no studies on this matter have been conducted. Certain other MAOIs, like iproniazid, phenelzine, pheniprazine, and tranylcypromine, but not nialamide, have likewise been found to produce amphetamine- and psychostimulant-like effects at high doses in animals. Several of these agents are known to metabolize into phenethylamines and amphetamines with catecholamine-releasing activity or to have intrinsic catecholamine-releasing actions of their own. Benzylamine derivatives have been found to act as catecholamine reuptake inhibitors.[36–43] WP

Pargyline has been found to act as an irreversible aldehyde dehydrogenase (ALDH) inhibitor. It is a disulfiram-like drug and can produce intolerance-type reactions with alcohol similarly to disulfiram. The ALDH inhibition of pargyline appears to be mediated by its metabolites, namely propiolaldehyde, but also propargylamine and benzylamine.[24][25] WP

Pargyline has been found to act as a reversible inhibitor of diamine oxidase (DAO)-mediated putrescine metabolism. It has additionally been found to act as a weak inhibitor of arylalkyl acylamidase and of histamine N-methyltransferase.[25][44][45][46] WP

In contrast to selegiline, pargyline does not appear to show catecholaminergic activity enhancer (CAE)-like effects. Similarly, pargyline is not an agonist of the mouse TAAR1.[31][32][47][48] WP

Pharmacokinetics

Pargyline has high lipophilicity and is predicted to cross the blood–brain barrier. The drug has been shown to elevate brain monoamine levels, for instance of serotonin norepinephrine, dopamine, and trace amines, in animals.[26][49][50][51] WP

Pargyline is N-demethylated and N-depropargylated by CYP2E1 to form arylalkylamine and other metabolites including benzylamine, N-methylbenzylamine, and N-propargylbenzylamine, among others. These metabolites may then undergo additional metabolism, for instance hydroxylation and oxidation. It also forms propiolaldehyde and propargylamine. N‐Propargylbenzylamine, which is a major active metabolite of pargyline, is a potent and selective inhibitor of MAO-B in vivo in rats and may contribute importantly to MAO-B inhibition with pargyline. Other metabolites, like propiolaldehyde, are potent ALDH inhibitors.[24][27][50][52][53] WP

Research

Research

Pargyline has been studied in the treatment of depression.[4][5][54–59] WP

History

History

Pargyline was first described in the scientific literature in 1960. It was brought to market in the United States and the United Kingdom by Abbott Laboratories in 1963 as an antihypertensive drug. It was one of several MAOIs introduced in the 1960s including nialamide, isocarboxazid, phenelzine, and tranylcypromine. By 2007, the drug was discontinued. As of 2014, there were no generic versions available in the United States. It continued to be available in the United States as late as 2000.[2][7][8][15–18][60–63] WP

Legal status

Names

Pargyline is the generic name of the drug and its INN (International Nonproprietary Name), BAN (British Approved Name), and DCF (Dénomination Commune Française), while its USAN (United States Adopted Name) and BANM (British Approved Name) in the case of the hydrochloride salt is pargyline hydrochloride. The drug is also known by the developmental code name MO-911. Marketed brand names of pargyline have included Eutonyl and Eutron.[1][2][12][26] WP

Chemistry

Formula

C11H13N PC

CAS number

555-57-7 PC

Molar mass (g/mol)

159.23 PC

IUPAC name (computed by PubChem)

N-benzyl-N-methylprop-2-yn-1-amine PC

SMILES

CN(CC#C)CC1=CC=CC=C1 PC

InChIKey

DPWPWRLQFGFJFI-UHFFFAOYSA-N PC

PubChem CID

4688

IUPAC name

N-benzyl-N-methylprop-2-yn-1-amine WP

Harm reduction information

No harm reduction data is on file for this compound yet. That means no dose, timing or combination data from PsychonautWiki or TripSit. Please don't guess a dose from similar compounds. If you have taken it and feel unwell, contact emergency services or a poison control center.

User reports

Pop culture

No references added yet.

Sources

1. Other Elks J. The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies. 2014
2. Other Schweizerischer Apotheker-Verein. Index Nominum 2000: International Drug Directory. 2000
3. Journal / agency Finberg JP. Update on the pharmacology of selective inhibitors of MAO-A and MAO-B: focus on modulation of CNS monoamine neurotransmitter release. Pharmacology & Therapeutics. August 2014. doi:10.1016/j.pharmthera.2014.02.010 · PMID 24607445
4. Journal / agency Kline NS, Cooper TB. Psychotropic Agents. 1980. doi:10.1007/978-3-642-67538-6_17
5. Journal / agency Murphy DL. The Behavioral Toxicity of Monoamine Oxidase-lnhibiting Antidepressants. 1977. doi:10.1016/s1054-3589(08)60185-4 · PMID 18913
6. Journal / agency Hayes AH, Schneck DW. Antihypertensive pharmacotherapy. Postgraduate Medicine. May 1976. doi:10.1080/00325481.1976.11714363 · PMID 57611
7. Journal / agency Eutonyl
8. Journal / agency Tipton KF. 90 years of monoamine oxidase: some progress and some confusion. Journal of Neural Transmission. November 2018. doi:10.1007/s00702-018-1881-5 · PMID 29637260
9. Journal / agency Abrams WB. The mechanisms of action of antihypertensive drugs. Diseases of the Chest. February 1969. doi:10.1378/chest.55.2.148 · PMID 4887212
10. Journal / agency McDonald RH. The evolution of current hypertension therapy. The American Journal of Medicine. September 1988. doi:10.1016/0002-9343(88)90344-0 · PMID 3048093
11. Journal / agency Mizgala HF. Newer Drugs in the Treatment of Hypertension. Canadian Medical Association Journal. April 1965. PMID 14289140 · PMC1928040
12. Other Morton IK, Hall JM. Concise Dictionary of Pharmacological Agents: Properties and Synonyms. 2012
13. Journal / agency Fowler CJ, Oreland L, Callingham BA. The acetylenic monoamine oxidase inhibitors clorgyline, deprenyl, pargyline and J-508: their properties and applications. The Journal of Pharmacy and Pharmacology. June 1981. doi:10.1111/j.2042-7158.1981.tb13800.x · PMID 6115003
14. Other Miklya I. The History of Selegiline/(-)-Deprenyl the First Selective Inhibitor of B-Type Monoamine Oxidase and The First Synthetic Catecholaminergic Activity Enhancer Substance. March 13, 2014
15. Journal / agency Ford RV. Clinical and pharmacologic observations on a monoamine oxidase inhibitor (pargyline hydrochloride) in hypertension. Current Therapeutic Research, Clinical and Experimental. September 1961. PMID 13700727
16. Journal / agency Bryant JM, Torosdag S, Schvartz N, Fletcher L, Fertig H, Schwartz MS, Quan RB. Antihypertensive properties of pargyline hydrochloride. New non-hydrazine monoamine oxidase inhibitor compared with sulphonamide diuretics. JAMA. October 1961. doi:10.1001/jama.1961.73040430005010 · PMID 13874134
17. Journal / agency Green AR, Haddad PM, Aronson JK. Marketing medicines: charting the rise of modern therapeutics through a systematic review of adverts in UK medical journals (1950-1980). British Journal of Clinical Pharmacology. August 2018. doi:10.1111/bcp.13549 · PMID 29442380 · PMC6046508
18. Journal / agency Pray WS. Interactions Between Nonprescription Products and Psychotropic Medications. US Pharmacist. 2007
19. Journal / agency Ragheb M. Drug interactions in psychiatric practice. International Pharmacopsychiatry. 1981. doi:10.1159/000468482 · PMID 6120917
20. Journal / agency Hurkmans JA. Reversal of the effect of α-methyldopa by monoamine oxidase inhibitors. The Journal of Pharmacy and Pharmacology. August 1963. doi:10.1111/j.2042-7158.1963.tb12824.x · PMID 14059015
21. Journal / agency van ROSSUM J. Potential dangers of monoamineoxidase inhibitors and alpha-methyldopa. Lancet. April 1963. doi:10.1016/S0140-6736(63)91728-8 · PMID 13975251
22. Journal / agency Paykel ES. Hallucinosis on combined methyldopa and pargyline. British Medical Journal. March 1966. doi:10.1136/bmj.1.5490.803-a · PMID 5910115 · PMC1844519
23. Journal / agency Hartshorn EA. Interactions of CNS Drugs Psychotherapeutic Agents — Antidepressants. Drug Intelligence & Clinical Pharmacy. 1974. doi:10.1177/106002807400801006
24. Journal / agency Koppaka V, Thompson DC, Chen Y, Ellermann M, Nicolaou KC, Juvonen RO, Petersen D, Deitrich RA, Hurley TD, Vasiliou V. Aldehyde dehydrogenase inhibitors: a comprehensive review of the pharmacology, mechanism of action, substrate specificity, and clinical application. Pharmacological Reviews. July 2012. doi:10.1124/pr.111.005538 · PMID 22544865 · PMC3400832
25. Journal / agency Holt A, Berry MD, Boulton AA. On the binding of monoamine oxidase inhibitors to some sites distinct from the MAO active site, and effects thereby elicited. Neurotoxicology. January 2004. doi:10.1016/S0161-813X(03)00104-9 · PMID 14697900
26. Harm reduction site Pargyline: Uses, Interactions, Mechanism of Action. 29 August 2007
27. Journal / agency Yamada M, Yasuhara H. Clinical pharmacology of MAO inhibitors: safety and future. Neurotoxicology. January 2004. doi:10.1016/S0161-813X(03)00097-4 · PMID 14697896
28. Journal / agency Fisar Z, Hroudová J, Raboch J. Inhibition of monoamine oxidase activity by antidepressants and mood stabilizers. Neuro Endocrinology Letters. 2010. PMID 21200377
29. Journal / agency Murphy DL, Karoum F, Pickar D, etal. MAO — the Mother of all Amine Oxidases. 1998. doi:10.1007/978-3-7091-6499-0_5 · PMID 9564606
30. Other Paul W, Szelenyi I. Inhibitors of Monoamine Oxidase B: Pharmacology and Clinical Use in Neurodegenerative Disorders. 1993
31. Journal / agency Knoll J. Deprenyl (selegiline): the history of its development and pharmacological action. Acta Neurol Scand Suppl. 1983. doi:10.1111/j.1600-0404.1983.tb01517.x · PMID 6428148
32. Journal / agency Magyar, K. Milestones in Drug Therapy. 1993. doi:10.1007/978-3-0348-6348-3_6
33. Journal / agency Hicks TP. The possible role of octopamine as a synaptic transmitter: a review. Canadian Journal of Physiology and Pharmacology. April 1977. doi:10.1139/y77-022 · PMID 17454
34. Journal / agency Oxenkrug GF. Antidepressive and antihypertensive effects of MAO-A inhibition: role of N-acetylserotonin. A review. Neurobiology. 1999. PMID 10591054
35. Journal / agency Piletz JE, Halaris A, Ernsberger PR. Psychopharmacology of imidazoline and α₂-adrenergic receptors: implications for depression. Critical Reviews in Neurobiology. 1995. PMID 8828003
36. Journal / agency Kitanaka J, Kitanaka N, Takemura M. Modification of Monoaminergic Activity by MAO Inhibitors Influences Methamphetamine Actions. Drug Target Insights. 2006. doi:10.1177/117739280600100001 · PMID 21901055 · PMC3155216
37. Journal / agency Barbelivien A, Nyman L, Haapalinna A, Sirviö J. Inhibition of MAO-A activity enhances behavioural activity of rats assessed using water maze and open arena tasks. Pharmacology & Toxicology. June 2001. doi:10.1034/j.1600-0773.2001.880604.x · PMID 11453370
38. Journal / agency Baker GB, Coutts RT. Metabolism of monoamine oxidase inhibitors. Progress in Neuro-Psychopharmacology & Biological Psychiatry. 1989. doi:10.1016/0278-5846(89)90128-0 · PMID 2664891
39. Journal / agency Spencer PS. Review of the pharmacology of existing antidepressants. British Journal of Clinical Pharmacology. 1977. doi:10.1111/j.1365-2125.1977.tb05761.x · PMID 334231 · PMC1429129
40. Journal / agency Baker GB, Coutts RT, McKenna KF, Sherry-McKenna RL. Insights into the mechanisms of action of the MAO inhibitors phenelzine and tranylcypromine: a review. Journal of Psychiatry & Neuroscience. November 1992. PMID 1362653 · PMC1188458
41. Journal / agency Ulrich S, Ricken R, Adli M. Tranylcypromine in mind (Part I): Review of pharmacology. European Neuropsychopharmacology. August 2017. doi:10.1016/j.euroneuro.2017.05.007 · PMID 28655495
42. Journal / agency Ricken R, Ulrich S, Schlattmann P, Adli M. Tranylcypromine in mind (Part II): Review of clinical pharmacology and meta-analysis of controlled studies in depression. European Neuropsychopharmacology. August 2017. doi:10.1016/j.euroneuro.2017.04.003 · PMID 28579071
43. Journal / agency Kammerer RC, Amiri B, Cho AK. Inhibition of uptake of catecholamines by benzylamine derivatives. Journal of Medicinal Chemistry. April 1979. doi:10.1021/jm00190a004 · PMID 430475
44. Journal / agency Sourkes TL, Missala K. Action of inhibitors on monoamine and diamine metabolism in the rat. Canadian Journal of Biochemistry. January 1977. doi:10.1139/o77-010 · PMID 402175
45. Journal / agency Hsu LL. Pineal aryl acylamidase: effects of melatonin, serotonin-related compounds, beta-carbolines, RO4-4602 and antidepressants. Research Communications in Chemical Pathology and Pharmacology. February 1984. PMID 6709961
46. Journal / agency Boudíková-Girard B, Scott MC, Weinshilboum R. Histamine N-methyltransferase: inhibition by monoamine oxidase inhibitors. Agents and Actions. September 1993. doi:10.1007/BF01976745 · PMID 8147263
47. Journal / agency Yen TT, Dalló J, Knoll J. The aphrodisiac effect of low doses of (-) deprenyl in male rats. Pol J Pharmacol Pharm. 1982. PMID 6821215
48. Journal / agency Wolinsky TD, Swanson CJ, Smith KE, Zhong H, Borowsky B, Seeman P, Branchek T, Gerald CP. The Trace Amine 1 receptor knockout mouse: an animal model with relevance to schizophrenia. Genes Brain Behav. October 2007. doi:10.1111/j.1601-183X.2006.00292.x · PMID 17212650
49. Journal / agency Pargyline
50. Journal / agency Karoum F. Neuropsychopharmacology of the Trace Amines. 1985. doi:10.1007/978-1-4612-5010-4_30
51. Journal / agency Spector S, Hirsch C, Brodie B. Association of behavoural effects of pargyline, a non-hydrazide mao inhibitor with increase in brain norepinephrine. International Journal of Neuropharmacology. 1963. doi:10.1016/0028-3908(63)90037-6
52. Journal / agency Baker GB, Urichuk LJ, McKenna KF, Kennedy SH. Metabolism of monoamine oxidase inhibitors. Cellular and Molecular Neurobiology. June 1999. doi:10.1023/a:1006901900106 · PMID 10319194 · PMC11545467
53. Journal / agency Karoum F. N-propargylbenzylamine, a major metabolite of pargyline, is a potent inhibitor of monoamine oxidase type B in rats in vivo: a comparison with deprenyl. British Journal of Pharmacology. February 1987. doi:10.1111/j.1476-5381.1987.tb08963.x · PMID 3103805 · PMC1916954
54. Journal / agency Bucci L, Henderson CT, Saunders JC. Pargyline, a paragon of affective therapy. Psychosomatics. 1962. doi:10.1016/s0033-3182(62)72680-0 · PMID 13874209
55. Journal / agency Oltman JE, Friedman S. Pargyline in the Treatment of Depressive Illnesses. The American Journal of Psychiatry. November 1963. doi:10.1176/ajp.120.5.493 · PMID 14054108
56. Journal / agency Saunders JC. Treatment of hospitalized depressed and schizophrenic patients with monoamine oxidase inhibitors: including reflections on pargyline. Annals of the New York Academy of Sciences. July 1963. doi:10.1111/j.1749-6632.1963.tb13351.x · PMID 13986821
57. Journal / agency Janecek J, Schiele BC, Vestre ND. Pargyline and Tranylcypromine in the Treatment of Hospitalized Depressed Patients. The Journal of New Drugs. 1963. doi:10.1002/j.1552-4604.1963.tb00084.x · PMID 14089807
58. Journal / agency Stern FH. Pargyvine hydrochloride: a new agent for the control of hypertension and mental depression. Journal of the American Geriatrics Society. July 1963. doi:10.1111/j.1532-5415.1963.tb02616.x · PMID 13983943
59. Journal / agency Ayd FJ. A clinical evaluation of pargyline hydrochloride (Eutonyl) in the management of mental depression. International Journal of Neuropsychiatry. 1965. PMID 14309088
60. Other Shorter E. A Historical Dictionary of Psychiatry. 2005
61. Other Wardell WM, Lasagna L. Regulation Drug Development. 1975
62. Journal / agency Council on Drugs' Statements. New Drugs and Developments in Therapeutics: Pargyline Hydrochloride (Eutonyl). JAMA. 1963. doi:10.1001/jama.1963.03700240079013
63. Journal / agency Eutonyl and MAO inhibitors. Drug and Therapeutics Bulletin. 15 November 1963. doi:10.1136/dtb.1.15.59

Text and values on this page are quoted from Wikipedia (CC BY-SA 4.0), PubChem (public domain). Each value links to the exact revision it came from.